Drugs /

zolbetuximab

Back to Drugs List

Overview

NCI Definition [1]:
A chimeric monoclonal antibody directed against the antigen GC182 with potential immunostimulatory and antineoplastic activities. Upon administration, claudiximab specifically binds to GC128, which may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GC182-expressing tumor cells, resulting in decreased tumor cell proliferation. The CD20-like antigen GC182, a gastric differentiation protein, is often overexpressed on the cell surfaces of a variety of tumor cells, including gastric, pancreatic, esophageal cancer and non-small cell lung cancer (NSCLC) cells.

Clinical Trials

View Clinical Trials for zolbetuximab

Zolbetuximab has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating zolbetuximab, 2 are phase 2 (2 open) and 2 are phase 3 (2 open).

CLDN18 Expression, CLDN18 Overexpression, and Claudin-18 isoform 2 Expression are the most frequent biomarker inclusion criteria for zolbetuximab clinical trials.

Adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and pancreatic adenocarcinoma are the most common diseases being investigated in zolbetuximab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Zolbetuximab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating zolbetuximab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
imab362, claudiximab, imab362, imab 362, imab-362
Drug Target(s) [2]:
CLDN18
NCIT ID [1]:
C85475

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.